IP Library › Assignment 073778/0476
Patent Assignment
Reel/Frame 073778/0476

Assignment of Assignor's Interest

Recorded: 2026-02-13 Pages: 20
Assignor
GALERA LABS, LLC
Executed: 2025-10-15
Assignee
BIOSSIL INC.
435 RICHMOND STREET WEST, UNIT 1013, TORONTO, M5V 0N3, CANADA
Covered Properties (31)
Methods of Treating Oral Mucositis
Patent: 9,855,279 →
Application: 11/871,848 →
Publication: US US20080269185A1
Combination Antitumor Therapy
Patent: 9,198,893 →
Application: 12/993,140 →
Publication: US US20110136756A1
Methods for Treatment of Diseases
Patent: 9,149,483 →
Application: 13/625,617 →
Publication: US US20130079317A1
Methods for Treatment of Diseases
Application: 14/837,831 →
Publication: US US20160151383A1
Methods of Treating Oral Mucositis
Patent: 9,642,861 →
Application: 14/302,082 →
Publication: US US20140343028A1
Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability
Application: 15/751,495 →
Publication: US US20180237462A1
Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability
Patent: 9,738,670 →
Application: 15/246,830 →
Publication: US US20170042907A1
Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability
Patent: 9,738,669 →
Application: 15/246,788 →
Publication: US US20170044193A1
Combination Cancer Therapy with Pentaaza Macrocyclic Ring Complex and Platinum-Based Anticancer Agent
Application: 16/965,476 →
Publication: US US20210338686A1
Methods of Treating Oral Mucositis
Application: 15/841,586 →
Publication: US US20180333421A1
Methods for Treatment of Diseases
Application: 16/176,958 →
Publication: US US20190240233A1
Combination Therapy for Cancer Treatment
Application: 16/098,026 →
Publication: US US20190151331A1
Combination Cancer Therapy with Pentaaza Macrocyclic Ring Complex and Ascorbate Compound
Application: 16/329,900 →
Publication: US US20190209524A1
Combination Cancer Therapy with Pentaaza Macrocyclic Ring Complex and Ascorbate Compound
Application: 17/538,790 →
Publication: US US20220304977A1
Combination Cancer Immunotherapy with Pentaaza Macrocyclic Ring Complex
Application: 16/604,872 →
Publication: US US20200376148A1
Combination Cancer Immunotherapy with Pentaaza Macrocyclic Ring Complex
Application: 17/566,335 →
Publication: US US20220118119A1
Methods for Treatment of Diseases
Application: 16/680,844 →
Publication: US US20220088030A1
Methods of Treating Oral Mucositis
Application: 16/802,916 →
Publication: US US20200215077A1
Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability
Application: 16/812,740 →
Publication: US US20200223879A1
Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability
Application: 17/378,852 →
Publication: US US20210347796A1
Manufacture Method for Aqueous Formulation of Manganese-Containing Coordination Complex, Formulation, and Method of Treatment
Application: 19/348,626 →
Publication: US US20260092079A1
Combination Cancer Therapy with Pentaaza Macrocyclic Ring Complex and Hormone Therapy Agent
Application: 18/071,724 →
Publication: US US20230149358A1
Combination Cancer Therapy with Pentaaza Macrocyclic Ring Complex and Hormone Therapy Agent
Application: 18/072,223 →
Publication: US US20230158042A1
Methods for Treatment of Diseases
Application: 19/334,255 →
Publication: US US20260076977A1
Crystalline Forms of Pentaaza Macrocyclic Ring Complex
Application: 18/598,251 →
Publication: US US20240300988A1
Crystalline Forms of Pentaaza Macrocyclic Ring Complex
Application: 18/598,269 →
Publication: US US20250073244A1
Method of Manufacture of Pentaaza Macrocyclic Ring Complex, Intermediates, and Products Thereof
Application: 18/598,300 →
Publication: US US20250109158A1
Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability
Application: 19/172,288 →
Publication: US US20260042790A1
Therapy for Reduced Ototoxicity from Chemotherapeutic Agent with Pentaaza Macrocyclic Ring Complex
Application: 19/035,011 →
Publication: US US20250387406A1
Methods for Reduced Tissue Damage from Radiopharmaceuticals with Superoxide-Reducing Agent
Carcinogenesis Reduction with Pentaaza Macrocyclic Ring Complex
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest Apr 8, 2010
From: HORIZON TECHNOLOGY FUNDING COMPANY, LLC
To: ACTIVBIOTICS, INC
Reel/Frame 024202/0367 →
Assignment of Assignor's Interest Apr 8, 2010
From: ACTIVBIOTICS, INC
To: KEREOS, INC; INOTEK PHARMACEUTICAL CORPORATION
Reel/Frame 024206/0733 →
Assignment of Assignor's Interest Apr 8, 2010
From: WONG, VIVIEN; ROTHSTEIN, DAVID M; MURPHY, CHRIS; KAZO, GLENN
To: ACTIVBIOTICS, INC
Reel/Frame 024206/0312 →
Assignment of Assignor's Interest Jul 20, 2012
From: KEENE, JEFFERY L.; RILEY, DENNIS P.; BEARDSLEY, ROBERT A.
To: KEREOS, INC.
Reel/Frame 028594/0953 →
Assignment of Assignor's Interest Aug 8, 2012
From: BUCKLER, PHILLIP M.; BEARDSLEY, ROBERT A.
To: GALERA THERAPEUTICS
Reel/Frame 028751/0156 →
Assignment of Assignor's Interest Aug 9, 2012
From: BUCKLER, PHILLIP M.; BEARDSLEY, ROBERT A.
To: GALERA THERAPEUTICS
Reel/Frame 028754/0606 →
Assignment of Assignor's Interest Nov 14, 2013
From: KEENE, JEFFREY L; RILEY, DENNIS P; BEARDSLEY, ROBERT A
To: GALERA THERAPEUTICS LLC
Reel/Frame 031600/0258 →
Assignment of Assignor's Interest Mar 27, 2015
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 035277/0507 →
Assignment of Assignor's Interest Mar 27, 2015
From: KEREOS, INC.
To: GALERA THERAPEUTICS, LLC
Reel/Frame 035276/0653 →
Assignment of Assignor's Interest Mar 27, 2015
From: ACTIVBIOTICS, INC.; METAPHORE PHARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 035277/0313 →
Assignment of Assignor's Interest Apr 14, 2015
From: WONG, VIVIEN; ROTHSTEIN, DAVID M.; MURPHY, CHRIS; KAZO, GLENN
To: ACTIVBIOTICS, INC
Reel/Frame 035406/0464 →
Change of Name Aug 12, 2015
From: GALERA THERAPEUTICS LLC
To: GALERA LABS, LLC
Reel/Frame 036306/0440 →
Change of Name Aug 26, 2015
From: GALERA THERAPEUTICS, LLC
To: GALERA LABS, LLC
Reel/Frame 036427/0622 →
Assignment of Assignor's Interest Mar 30, 2016
From: KEENE, JEFFERY L.; RILEY, DENNIS P.; BEARDSLEY, ROBERT A.
To: GALERA THERAPEUTICS LLC
Reel/Frame 038134/0212 →
Change of Name Mar 30, 2016
From: GALERA THERAPEUTICS LLC
To: GALERA LABS, LLC
Reel/Frame 038134/0294 →
Assignment of Assignor's Interest Aug 25, 2016
From: SCHALL, OTTO F.; KEENE, JEFFREY L.; RILEY, DENNIS P.
To: GALERA LABS, LLC
Reel/Frame 039539/0438 →
Assignment of Assignor's Interest Aug 25, 2016
From: KEENE, JEFFREY L.; RILEY, DENNIS P.; SCHALL, OTTO F.
To: GALERA LABS, LLC
Reel/Frame 039539/0177 →
Assignment of Assignor's Interest Dec 14, 2017
From: WONG, VIVIEN; ROTHSTEIN, DAVID M.; MURPHY, CHRIS; KAZO, GLENN
To: ACTIVBIOTICS, INC
Reel/Frame 044396/0268 →
Assignment of Assignor's Interest Feb 9, 2018
From: RILEY, DENNIS P.; SCHALL, OTTO F.; KEENE, JEFFERY L.
To: GALERA LABS, LLC
Reel/Frame 044877/0972 →
Change of Name Aug 29, 2018
From: GALERA THERAPEUTICS, LLC
To: GALERA LABS, LLC
Reel/Frame 046743/0868 →
License Aug 29, 2018
From: INOTEK PHARMACEUTICALS CORPORATION
To: GALERA THERAPEUTICS, LLC
Reel/Frame 046971/0563 →
Assignment of Assignor's Interest Aug 29, 2018
From: ACTIVBIOTICS, INC; METAPHORE PARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 046971/0624 →
Bill of Sale Aug 29, 2018
From: ACTIVBIOTICS, INC.; METAPHORE PHARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 046971/0656 →
Assignment of Assignor's Interest Aug 29, 2018
From: KEENE, JEFFREY LYNN
To: KEREOS, INC.
Reel/Frame 046975/0046 →
Bill of Sale Aug 29, 2018
From: ACTIVBIOTICS, INC.; METAPHORE PHARMACEUTICALS, INC.
To: KEREOS, INC.; INOTEK PHARMACEUTICALS CORPORATION
Reel/Frame 046975/0848 →